Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Suptavumab (REGN2222) in Healthy Volunteers
NCT02121080Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2014
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of suptavumab in respiratory syncytial virus infection (RSV) (5 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events. Started May 2014; status: completed.
02
Drugs
suptavumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02121080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02121080.